Nat Med 27(8):14711476
That may include different treatments for a targeted approach
Yet trials on another GHRH-mimetic, more specifically the non-truncated and unmodified version of Mod GRF 1-29 which has shorter half life, appear to lead to a 20-fold increase in pulsatile growth hormone secretion
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice
The paper reports that seven of the nine patients had a NAION-like presentation